Last reviewed · How we verify
Hunterase (IDURSULFASE BETA)
Hunterase (IDURSULFASE BETA) is a small molecule drug developed by Clinigen K.K. for the treatment of Mucopolysaccharidosis type II. It is a replacement enzyme therapy that works by breaking down and removing excess mucopolysaccharides in the body. Hunterase is currently owned by Clinigen K.K. and is used to manage the symptoms of this rare genetic disorder. The commercial status of Hunterase is not publicly disclosed.
At a glance
| Generic name | IDURSULFASE BETA |
|---|---|
| Sponsor | Clinigen K.K. |
| Modality | Enzyme |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Mucopolysaccharidosis type II
Common side effects
Key clinical trials
- An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) (PHASE3)
- A Study of GC1111 in Hunter Syndrom Patients (PHASE3)
- Study of Idursulfase-beta (GC1111) in Hunter Syndrome (PHASE2)
- Safety and Efficacy of Hunterase (PHASE3)
- The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hunterase CI brief — competitive landscape report
- Hunterase updates RSS · CI watch RSS
- Clinigen K.K. portfolio CI